Tech Center 1700 • Art Units: 1644 1646 1678 1783
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17427222 | METHOD FOR DETECTING CELLS | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 16980128 | IMMUNO-EXOSOMES AND METHODS OF USE THEREOF | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17776131 | SYSTEMS AND METHODS FOR RAPID, SENSITIVE MULTIPLEX IMMUNOASSAYS | Non-Final OA | The Regents of the University of Michigan |
| 17924748 | DETECTION METHOD OF TARGET MOLECULE IN SPECIMEN AND DETECTION KIT FOR TARGET MOLECULE | Non-Final OA | Yokogawa Electric Corporation |
| 17423133 | METHOD FOR SELECTING CELLS HIGHLY RESPONSIVE TO TARGET SUBSTANCE, AND METHOD FOR DETERMINING CONCENTRATION OF TARGET SUBSTANCE WITH UNKNOWN CONCENTRATION IN SPECIMEN | Final Rejection | HAMAMATSU PHOTONICS K.K. |
| 18625703 | NOVEL PD-1 BINDING DOMAINS | Final Rejection | INCYTE CORPORATION |
| 18024603 | CONJUGATES HAVING AN ENZYMMATICALLY RELEASABLE DETECTION MOIETY AND A BARCODE MOIETY | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 18065736 | MEASURING FREQUENCY OF PATHOGEN-SPECIFIC T CELLS IN PERIPHERAL BLOOD | Non-Final OA | Thomas Jefferson University |
| 18032597 | IMPROVED DETECTION OF LYMPHOCYTE - TARGET CELL INTERACTION | Non-Final OA | LUMICKS CA HOLDING B.V. |
| 18447623 | Use of Anti-Il-6 Antibody, e.g., Clazakizumab for Desensitization of Solid Organ Transplant Recipients and/or for Preventing, Stabilizing or Reducing Antibody Mediated Rejection (ABMR) | Non-Final OA | CEDARS-SINAI MEDICAL CENTER |
| 16961026 | Fusion Protein Extensions | Final Rejection | NantBio, Inc. |
| 17128599 | BISPECIFIC SIGNALING AGENTS AND USES THEREOF | Final Rejection | Universiteit Gent |
| 17056626 | Composition of Concentrated Human Immunoglobulins | Final Rejection | Laboratoire Francais du Fractionnement et des Biotechnologies |
| 17294327 | METHODS AND REAGENTS FOR MULTIPLEX BINDING EXPERIMENTS | Non-Final OA | BIOASTER |
| 18277237 | Immunoassay for Detecting Eosinophilic Esophagitis | Non-Final OA | Nordic Bioscience A/S |
| 17925999 | HYPER-SIALYLATED IMMUNOGLOBULIN | Final Rejection | Momenta Pharmaceuticals, Inc. |
| 17292588 | METHOD FOR PREVENTING IRREGULAR DETECTION IN IMMUNOASSAY IN AUTOMATIC ANALYZER, AND IMMUNOASSAY REAGENT | Non-Final OA | SEKISUI MEDICAL CO., LTD. |
| 18112527 | ANTIBODY COMBINATION FOR SUBSTITUTING SIDE SCATTER SIGNAL IN MASS CYTOMETRY HEMATOLOGIC TUMOR IMMUNOPHENOTYPING AND USE THEREOF | Final Rejection | Zhejiang Puluoting Health Technology Co., Ltd. |
| 18109628 | IMMUNOSTAINING USING PROTEIN CONJUGATES | Non-Final OA | Advanced Biosystems, Inc. |
| 17759742 | MACROMOLECULES ENGINEERED FOR NANOELECTRONIC MEASUREMENT | Non-Final OA | Universal Sequencing Technology Corporation |
| 18008155 | A METHOD FOR DETERMINING KINETIC PARAMETERS OF A REACTION | Final Rejection | Creoptix AG |
| 17964053 | NITROGEN-SULFUR CO-DOPED TI3C2-MXENE NANOSHEET AND PREPARATION METHOD AND APPLICATION THEREOF | Non-Final OA | Civil Aviation University of China |
| 17819810 | TUMOR SUPPRESSION BY MODULATION OF NON-CANONICAL AUTOPHAGY (LAP) IN MYELOID CELLS | Non-Final OA | St. Jude Children's Research Hospital |
| 17618004 | BIOMARKER FOR DIAGNOSIS OF CEREBRAL NERVOUS SYSTEM DISEASES | Final Rejection | UNIVERSITY-INDUSTRY COOP. GROUP, KYUNG HEE UNIV. |
| 17607333 | Screening Methods and Assays for Use with Transmembrane Proteins, in Particular with GPCRs | Final Rejection | CONFO THERAPEUTICS N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy